Retatrutide is an investigational once-weekly injectable peptide that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved single or dual receptor agonists such as semaglutide and tirzepatide
We also offer treatments you can combine with GLP-1 for amplified results, such as B12 injections and Tone body contouring
The Lancet Diabetes & Endocrinology, 2025
[DOI] [PMC free article] [PubMed] [Google Scholar] 65.de Guia R.M., Agerholm M., Nielsen T.S., Consitt L.A., Sgaard D., Helge J.W., Larsen S., Brandauer J., Houmard J.A., Treebak J.T
Fluctuations in refrigerator temperature can affect the medications chemical stability and shorten its usable life
Nutritional intake Ask: Is the patient eating regular meals